Abstract
Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Current Pharmaceutical Design
Title: Bisphosphonate Therapy in the Treatment of Multiple Myeloma
Volume: 16 Issue: 27
Author(s): M. A. Lawson, J. Ashcroft and P. I. Croucher
Affiliation:
Keywords: Bisphosphonates, myeloma, anti-resorptive, anti-tumour, bone, osteoclasts, osteolytic lesions, Multiple Myeloma, M-spike, M-protein, Bence-Jones Protein, lymphatohaemopoietic cancer, Osteoclast-derived molecules, dickkopf-1 (DKK1), frizzled-related protein (sFRP)-2, myeloma-derived DKK1, MM-derived osteoclasts, anti-DKK1, OSTEOCLAST INHIBITION, clodronate (CLOD), etidronate (ETID), protein prenylation, bone mineral density (BMD), Anti-Tumour Effects, anti-resorptive potency, SCID-hu model, Angiogenesis, Bisphosphoante-Associated Osteonecrosis of the Jaw (BONJ), vascular insufficiency, B-cell activating factor, Hepatocyte growth factor, Interleukin 1 alpha
Abstract: Multiple myeloma is an incurable B cell neoplasm caused by the monoclonal expansion of malignant plasma cells in the bone marrow, often resulting in devastating bone disease. For over 2 decades bisphosphonates have been successfully used to treat the tumourinduced bone disease associated with multiple myeloma. This review will focus on preclinical studies and investigations in patients with multiple myeloma that have led to our current understanding of the mechanisms of action of bisphosphonates in myeloma bone disease. Major advances in the use of bisphosphonates, including findings that they may have additional benefits such as anti-tumour effects and promoting patient survival will be discussed.
Export Options
About this article
Cite this article as:
A. Lawson M., Ashcroft J. and I. Croucher P., Bisphosphonate Therapy in the Treatment of Multiple Myeloma, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563608
DOI https://dx.doi.org/10.2174/138161210793563608 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers
Mini-Reviews in Medicinal Chemistry The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry A Dual Role for Sirtuin 1 in Tumorigenesis
Current Pharmaceutical Design Interaction of ABC Multidrug Transporters with Anticancer Protein Kinase Inhibitors: Substrates and/or Inhibitors?
Current Cancer Drug Targets α-Methylene-γ-lactones as a Novel Class of Anti-leukemic Agents
Anti-Cancer Agents in Medicinal Chemistry Insect Peptides – Perspectives in Human Diseases Treatment
Current Medicinal Chemistry The Functions of Polo-Like Kinases and their Relevance to Human Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Current Medicinal Chemistry Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy Synthesis and Anticancer Activity of Phthalimido and Naphthalimido Substituted Dihydropyrimidone Conjugates
Letters in Drug Design & Discovery Seek and Destroy: The Use of Natural Compounds for Targeting the Molecular Roots of Cancer
Current Drug Targets Advances in Immunotherapy of Chronic Myeloid Leukemia CML
Current Cancer Drug Targets